

**Appendix 1: Correlation between Hs-CRP grouping and patient age in CRC**

|                |              |                     | <b>Hs-CRP<br/>grouping</b> | <b>Age</b> |
|----------------|--------------|---------------------|----------------------------|------------|
| <b>Pearson</b> | Hs-CRP group | Pearson correlation | 1.000                      | 0.196      |
|                |              | Sig. (Two-tailed)   | -                          | 0.001***   |
|                |              | n                   | 281                        | 281        |
|                | Age          | Pearson correlation | 0.196                      | 1.000      |
|                |              | Sig. (Two-tailed)   | 0.001***                   | -          |
|                |              | n                   | 281                        | 281        |

Hs-CRP \*\*\* $P < 0.001$

**Appendix 2: Correlation between Hs-CRP grouping and tumor diameter in CRC patients**

|                |                |                     | <b>Hs-CRP<br/>grouping</b> | <b>Tumor<br/>diameter</b> |
|----------------|----------------|---------------------|----------------------------|---------------------------|
| <b>Pearson</b> | Hs-CRP group   | Pearson correlation | 1.000                      | 0.133                     |
|                |                | Sig. (Two-tailed)   | -                          | 0.026*                    |
|                |                | n                   | 281                        | 281                       |
|                | Tumor diameter | Pearson correlation | 0.133                      | 1.000                     |
|                |                | Sig. (Two-tailed)   | 0.026*                     | -                         |
|                |                | n                   | 281                        | 281                       |

\* $P < 0.05$

**Appendix 3: Correlation between Hs-CRP grouping and tumor location in CRC patients**

|                |                |                     | <b>Hs-CRP<br/>group</b> | <b>Tumor<br/>diameter</b> |
|----------------|----------------|---------------------|-------------------------|---------------------------|
| <b>Pearson</b> | Hs-CRP group   | Pearson correlation | 1.000                   | -0.132                    |
|                |                | Sig. (Two-tailed)   | -                       | 0.027*                    |
|                |                | n                   | 281                     | 281                       |
|                | Tumor diameter | Pearson correlation | -0.132                  | 1.000                     |

|  |                   |        |     |
|--|-------------------|--------|-----|
|  | Sig. (Two-tailed) | 0.027* | -   |
|  | n                 | 281    | 281 |

\* $P < 0.05$

#### Appendix 4: Univariate analysis of preoperative inflammatory indicators and Ki-67 expression in CRC

|                          | Ki-67<70%<br>(n=35)    | Ki-67≥70%<br>(n=246)   | P value |
|--------------------------|------------------------|------------------------|---------|
| WBC (10 <sup>9</sup> /L) | 6.14 (4.84-7.66)       | 5.98 (4.84-7.39)       | 0.678   |
| Hs-CRP (mg/L)            | 4.02 (0.6-6.62)        | 2.74 (0.96-13.69)      | 0.279   |
| NLR                      | 2.72 (1.92-3.76)       | 2.33 (1.69-3.63)       | 0.279   |
| PLR                      | 171.58 (131.41-245.51) | 148.56 (105.11-195.87) | 0.071   |
| SII                      | 679.15 (446.70-985.11) | 504.19 (336.36-850.46) | 0.093   |

#### Appendix 5: Univariate analysis of preoperative inflammatory indicators according to lymph node metastasis status in CRC

|                          | Absence of lymph node<br>metastasis<br>(n=171) | Lymph node<br>metastasis<br>(n=110) | P value |
|--------------------------|------------------------------------------------|-------------------------------------|---------|
| WBC (10 <sup>9</sup> /L) | 6.18 (5.07-7.65)                               | 5.82 (4.72-7.07)                    | 0.075   |
| Hs-CRP (mg/L)            | 2.55 (0.89-10.2)                               | 4.13 (0.89-15.36)                   | 0.275   |
| NLR                      | 2.48 (1.69-4.07)                               | 2.24 (1.73-3.36)                    | 0.284   |
| PLR                      | 143.33 (103.02-200.44)                         | 158.86 (115.72-200.59)              | 0.275   |
| SII                      | 545.11 (342.24-899.83)                         | 489.38 (359.35-906.90)              | 0.632   |

#### Appendix 6: Univariate analysis of preoperative inflammatory indicators across different TNM stages in CRC

|                          | Stage I and II (n=167) | Stage III (n=114)      | P value |
|--------------------------|------------------------|------------------------|---------|
| WBC (10 <sup>9</sup> /L) | 6.20 (5.12-7.65)       | 5.81 (4.71-7.07)       | 0.054   |
| Hs-CRP (mg/L)            | 2.55 (1.01-10.25)      | 4.10 (0.87-15.36)      | 0.366   |
| NLR                      | 2.52 (1.69-4.07)       | 2.24 (1.73-3.59)       | 0.249   |
| PLR                      | 143.33 (102.11-200.43) | 158.86 (116.66-200.56) | 0.229   |
| SII                      | 544.19 (336.85-927.16) | 500.93 (362.58-883.06) | 0.645   |

**Appendix 7: Multivariate logistic regression analysis of factors associated with tumor diameter in CRC patients**

| Clinicopathological feature | <i>P</i> value | OR value | 95%CI         |
|-----------------------------|----------------|----------|---------------|
| <b>WBC</b>                  | 0.168          | 1.134    | 0.948 ~ 1.356 |
| <b>NLR</b>                  | 0.010**        | 0.729    | 0.572 ~ 0.928 |
| <b>SII</b>                  | 0.013*         | 1.002    | 1.000 ~ 1.003 |

\* $P < 0.05$ ; \*\* $P < 0.01$

WBC: White Blood Cell

CRP: C-Reactive Protein

NLR: Neutrophil-to-Lymphocyte Ratio

PLR: Platelet-to-Lymphocyte Ratio

SLE: Systemic Lupus Erythematosus

MALT: Mucosa-Associated Lymphoid Tissue

TA1/E16: An oncofetal gene

SII: Systemic Immune-Inflammation Index